vascular cell adhesion molecule 1 Search Results


90
Randox vascular cell adhesion molecule vcam 1
Vascular Cell Adhesion Molecule Vcam 1, supplied by Randox, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pm27815221-56-6-37?v=Randox
Average 90 stars, based on 1 article reviews
vascular cell adhesion molecule vcam 1 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

93
Elabscience Biotechnology elabscience e el h5587
Elabscience E El H5587, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pm32456230-89-25-25?v=Elabscience+Biotechnology
Average 93 stars, based on 1 article reviews
elabscience e el h5587 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

90
OriGene human madcam1
Figure 1: Doxorubicin induced apoptosis and reduced <t>Madcam1</t> expression. A.-B. Doxo induced dose-dependent cleavage of Caspase substrates (CCS), as analyzed by WB using an anti-cleaved caspase substrate antibodies, in SMMC-7721 and Bel-7402 cells treated with DMSO or Doxo (final concentration 0.5-2.0 µg/ml) for 24 h. The representative western blots are shown in panel A. The CCS was calculated as the ratio between the levels of cleaved Caspase substrate and GAPDH, and the data are shown in panel B. The groups treated with 0.5 µg/ml Doxo were arbitrarily set to 100%. C. Doxo induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo luciferase kit from Promega, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. D. Doxo reduced cell proliferation, as measured by an MTT-based assay, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. E. Potential proteins that were regulated by Doxo. Endogenous expression of the indicated proteins were tested by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. The relative levels of Madcam1 protein expression in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h were calculated as the ratio between Madcam1 and GAPDH. The “DMSO” group was arbitrarily set to 100 %. G.-H. Exogenous Madcam1-Myc was measured in Bel-7402 transfected with GFP and Madcam1-Myc expressing plasmids and treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Representative WB images of are shown in panel G, the relative expression levels of exogenous Myc were calculated as the ratio to GFP, and the data are shown in panel H. The “DMSO” group was arbitrarily set to 100 %. I. Subcellular localization of Madcam1 in Bel-7402 and SMMC-7721 cells, as measured by the immunofluorescence assay. Scale bar, 5 µM. J. Madcam1 mRNA levels in Bel-7402 and SMMC-7721 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h, as measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The “DMSO” group was arbitrarily set to 100 %. K. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding DMSO or actinomycin D (final concentration 10 μg/ml) for further treatment for 24 h. Then, the RNA was extracted and measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The group treated with DMSO only was arbitrarily set to 100 %. L.-M. Doxo had no influence on Madcam1 protein stability. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 g/ml) for 2 h before being treated with CHX (final concentration 50 μg/ml) for the indicated times. Then, the cells were harvested for WB using anti-Madcam1 and anti-GAPDH antibodies L.. The Madcam1 protein levels were normalized to GAPDH, and the data are shown in panel M.. The group treated with CHX at the 0 h point was arbitrarily set to 100 %. N.-O. Time-dependent enrichment of eIF4E on the Madcam1 mRNA. Bel-7402 N. and SMMC- 7721 O. cells were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for the indicated times. Then, the RNA was extracted and subjected into RNA-IP assays using an anti-eIF4E antibody. The “0h” point was arbitrarily set to 100 %. **, Indicates statistical significance between “DMSO” and “Doxo” at specific time points. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.
Human Madcam1, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pm26124182-183-4-9?v=OriGene
Average 90 stars, based on 1 article reviews
human madcam1 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

93
Elabscience Biotechnology vcam 1
Figure 1: Doxorubicin induced apoptosis and reduced <t>Madcam1</t> expression. A.-B. Doxo induced dose-dependent cleavage of Caspase substrates (CCS), as analyzed by WB using an anti-cleaved caspase substrate antibodies, in SMMC-7721 and Bel-7402 cells treated with DMSO or Doxo (final concentration 0.5-2.0 µg/ml) for 24 h. The representative western blots are shown in panel A. The CCS was calculated as the ratio between the levels of cleaved Caspase substrate and GAPDH, and the data are shown in panel B. The groups treated with 0.5 µg/ml Doxo were arbitrarily set to 100%. C. Doxo induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo luciferase kit from Promega, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. D. Doxo reduced cell proliferation, as measured by an MTT-based assay, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. E. Potential proteins that were regulated by Doxo. Endogenous expression of the indicated proteins were tested by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. The relative levels of Madcam1 protein expression in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h were calculated as the ratio between Madcam1 and GAPDH. The “DMSO” group was arbitrarily set to 100 %. G.-H. Exogenous Madcam1-Myc was measured in Bel-7402 transfected with GFP and Madcam1-Myc expressing plasmids and treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Representative WB images of are shown in panel G, the relative expression levels of exogenous Myc were calculated as the ratio to GFP, and the data are shown in panel H. The “DMSO” group was arbitrarily set to 100 %. I. Subcellular localization of Madcam1 in Bel-7402 and SMMC-7721 cells, as measured by the immunofluorescence assay. Scale bar, 5 µM. J. Madcam1 mRNA levels in Bel-7402 and SMMC-7721 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h, as measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The “DMSO” group was arbitrarily set to 100 %. K. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding DMSO or actinomycin D (final concentration 10 μg/ml) for further treatment for 24 h. Then, the RNA was extracted and measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The group treated with DMSO only was arbitrarily set to 100 %. L.-M. Doxo had no influence on Madcam1 protein stability. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 g/ml) for 2 h before being treated with CHX (final concentration 50 μg/ml) for the indicated times. Then, the cells were harvested for WB using anti-Madcam1 and anti-GAPDH antibodies L.. The Madcam1 protein levels were normalized to GAPDH, and the data are shown in panel M.. The group treated with CHX at the 0 h point was arbitrarily set to 100 %. N.-O. Time-dependent enrichment of eIF4E on the Madcam1 mRNA. Bel-7402 N. and SMMC- 7721 O. cells were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for the indicated times. Then, the RNA was extracted and subjected into RNA-IP assays using an anti-eIF4E antibody. The “0h” point was arbitrarily set to 100 %. **, Indicates statistical significance between “DMSO” and “Doxo” at specific time points. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.
Vcam 1, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/10__2147_slash_dmso__s490055-38-55-59?v=Elabscience+Biotechnology
Average 93 stars, based on 1 article reviews
vcam 1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

93
Elabscience Biotechnology immunosorbent assay elisa kit
Figure 1: Doxorubicin induced apoptosis and reduced <t>Madcam1</t> expression. A.-B. Doxo induced dose-dependent cleavage of Caspase substrates (CCS), as analyzed by WB using an anti-cleaved caspase substrate antibodies, in SMMC-7721 and Bel-7402 cells treated with DMSO or Doxo (final concentration 0.5-2.0 µg/ml) for 24 h. The representative western blots are shown in panel A. The CCS was calculated as the ratio between the levels of cleaved Caspase substrate and GAPDH, and the data are shown in panel B. The groups treated with 0.5 µg/ml Doxo were arbitrarily set to 100%. C. Doxo induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo luciferase kit from Promega, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. D. Doxo reduced cell proliferation, as measured by an MTT-based assay, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. E. Potential proteins that were regulated by Doxo. Endogenous expression of the indicated proteins were tested by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. The relative levels of Madcam1 protein expression in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h were calculated as the ratio between Madcam1 and GAPDH. The “DMSO” group was arbitrarily set to 100 %. G.-H. Exogenous Madcam1-Myc was measured in Bel-7402 transfected with GFP and Madcam1-Myc expressing plasmids and treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Representative WB images of are shown in panel G, the relative expression levels of exogenous Myc were calculated as the ratio to GFP, and the data are shown in panel H. The “DMSO” group was arbitrarily set to 100 %. I. Subcellular localization of Madcam1 in Bel-7402 and SMMC-7721 cells, as measured by the immunofluorescence assay. Scale bar, 5 µM. J. Madcam1 mRNA levels in Bel-7402 and SMMC-7721 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h, as measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The “DMSO” group was arbitrarily set to 100 %. K. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding DMSO or actinomycin D (final concentration 10 μg/ml) for further treatment for 24 h. Then, the RNA was extracted and measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The group treated with DMSO only was arbitrarily set to 100 %. L.-M. Doxo had no influence on Madcam1 protein stability. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 g/ml) for 2 h before being treated with CHX (final concentration 50 μg/ml) for the indicated times. Then, the cells were harvested for WB using anti-Madcam1 and anti-GAPDH antibodies L.. The Madcam1 protein levels were normalized to GAPDH, and the data are shown in panel M.. The group treated with CHX at the 0 h point was arbitrarily set to 100 %. N.-O. Time-dependent enrichment of eIF4E on the Madcam1 mRNA. Bel-7402 N. and SMMC- 7721 O. cells were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for the indicated times. Then, the RNA was extracted and subjected into RNA-IP assays using an anti-eIF4E antibody. The “0h” point was arbitrarily set to 100 %. **, Indicates statistical significance between “DMSO” and “Doxo” at specific time points. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.
Immunosorbent Assay Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pmc08866968-54-11-15?v=Elabscience+Biotechnology
Average 93 stars, based on 1 article reviews
immunosorbent assay elisa kit - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

93
Proteintech vascular cell adhesion molecule 1
Figure 1: Doxorubicin induced apoptosis and reduced <t>Madcam1</t> expression. A.-B. Doxo induced dose-dependent cleavage of Caspase substrates (CCS), as analyzed by WB using an anti-cleaved caspase substrate antibodies, in SMMC-7721 and Bel-7402 cells treated with DMSO or Doxo (final concentration 0.5-2.0 µg/ml) for 24 h. The representative western blots are shown in panel A. The CCS was calculated as the ratio between the levels of cleaved Caspase substrate and GAPDH, and the data are shown in panel B. The groups treated with 0.5 µg/ml Doxo were arbitrarily set to 100%. C. Doxo induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo luciferase kit from Promega, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. D. Doxo reduced cell proliferation, as measured by an MTT-based assay, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. E. Potential proteins that were regulated by Doxo. Endogenous expression of the indicated proteins were tested by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. The relative levels of Madcam1 protein expression in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h were calculated as the ratio between Madcam1 and GAPDH. The “DMSO” group was arbitrarily set to 100 %. G.-H. Exogenous Madcam1-Myc was measured in Bel-7402 transfected with GFP and Madcam1-Myc expressing plasmids and treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Representative WB images of are shown in panel G, the relative expression levels of exogenous Myc were calculated as the ratio to GFP, and the data are shown in panel H. The “DMSO” group was arbitrarily set to 100 %. I. Subcellular localization of Madcam1 in Bel-7402 and SMMC-7721 cells, as measured by the immunofluorescence assay. Scale bar, 5 µM. J. Madcam1 mRNA levels in Bel-7402 and SMMC-7721 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h, as measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The “DMSO” group was arbitrarily set to 100 %. K. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding DMSO or actinomycin D (final concentration 10 μg/ml) for further treatment for 24 h. Then, the RNA was extracted and measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The group treated with DMSO only was arbitrarily set to 100 %. L.-M. Doxo had no influence on Madcam1 protein stability. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 g/ml) for 2 h before being treated with CHX (final concentration 50 μg/ml) for the indicated times. Then, the cells were harvested for WB using anti-Madcam1 and anti-GAPDH antibodies L.. The Madcam1 protein levels were normalized to GAPDH, and the data are shown in panel M.. The group treated with CHX at the 0 h point was arbitrarily set to 100 %. N.-O. Time-dependent enrichment of eIF4E on the Madcam1 mRNA. Bel-7402 N. and SMMC- 7721 O. cells were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for the indicated times. Then, the RNA was extracted and subjected into RNA-IP assays using an anti-eIF4E antibody. The “0h” point was arbitrarily set to 100 %. **, Indicates statistical significance between “DMSO” and “Doxo” at specific time points. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.
Vascular Cell Adhesion Molecule 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pmc08436971-46-22-31?v=Proteintech
Average 93 stars, based on 1 article reviews
vascular cell adhesion molecule 1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

93
Shanghai Korain Biotech Co Ltd elisa kits
Figure 1: Doxorubicin induced apoptosis and reduced <t>Madcam1</t> expression. A.-B. Doxo induced dose-dependent cleavage of Caspase substrates (CCS), as analyzed by WB using an anti-cleaved caspase substrate antibodies, in SMMC-7721 and Bel-7402 cells treated with DMSO or Doxo (final concentration 0.5-2.0 µg/ml) for 24 h. The representative western blots are shown in panel A. The CCS was calculated as the ratio between the levels of cleaved Caspase substrate and GAPDH, and the data are shown in panel B. The groups treated with 0.5 µg/ml Doxo were arbitrarily set to 100%. C. Doxo induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo luciferase kit from Promega, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. D. Doxo reduced cell proliferation, as measured by an MTT-based assay, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. E. Potential proteins that were regulated by Doxo. Endogenous expression of the indicated proteins were tested by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. The relative levels of Madcam1 protein expression in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h were calculated as the ratio between Madcam1 and GAPDH. The “DMSO” group was arbitrarily set to 100 %. G.-H. Exogenous Madcam1-Myc was measured in Bel-7402 transfected with GFP and Madcam1-Myc expressing plasmids and treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Representative WB images of are shown in panel G, the relative expression levels of exogenous Myc were calculated as the ratio to GFP, and the data are shown in panel H. The “DMSO” group was arbitrarily set to 100 %. I. Subcellular localization of Madcam1 in Bel-7402 and SMMC-7721 cells, as measured by the immunofluorescence assay. Scale bar, 5 µM. J. Madcam1 mRNA levels in Bel-7402 and SMMC-7721 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h, as measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The “DMSO” group was arbitrarily set to 100 %. K. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding DMSO or actinomycin D (final concentration 10 μg/ml) for further treatment for 24 h. Then, the RNA was extracted and measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The group treated with DMSO only was arbitrarily set to 100 %. L.-M. Doxo had no influence on Madcam1 protein stability. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 g/ml) for 2 h before being treated with CHX (final concentration 50 μg/ml) for the indicated times. Then, the cells were harvested for WB using anti-Madcam1 and anti-GAPDH antibodies L.. The Madcam1 protein levels were normalized to GAPDH, and the data are shown in panel M.. The group treated with CHX at the 0 h point was arbitrarily set to 100 %. N.-O. Time-dependent enrichment of eIF4E on the Madcam1 mRNA. Bel-7402 N. and SMMC- 7721 O. cells were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for the indicated times. Then, the RNA was extracted and subjected into RNA-IP assays using an anti-eIF4E antibody. The “0h” point was arbitrarily set to 100 %. **, Indicates statistical significance between “DMSO” and “Doxo” at specific time points. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.
Elisa Kits, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/10__21608_slash_aumj__2022__142334__1011-28-31-35?v=Shanghai+Korain+Biotech+Co+Ltd
Average 93 stars, based on 1 article reviews
elisa kits - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

91
Proteintech vascular cell adhesion molecule 1 vcam 1
Figure 1: Doxorubicin induced apoptosis and reduced <t>Madcam1</t> expression. A.-B. Doxo induced dose-dependent cleavage of Caspase substrates (CCS), as analyzed by WB using an anti-cleaved caspase substrate antibodies, in SMMC-7721 and Bel-7402 cells treated with DMSO or Doxo (final concentration 0.5-2.0 µg/ml) for 24 h. The representative western blots are shown in panel A. The CCS was calculated as the ratio between the levels of cleaved Caspase substrate and GAPDH, and the data are shown in panel B. The groups treated with 0.5 µg/ml Doxo were arbitrarily set to 100%. C. Doxo induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo luciferase kit from Promega, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. D. Doxo reduced cell proliferation, as measured by an MTT-based assay, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. E. Potential proteins that were regulated by Doxo. Endogenous expression of the indicated proteins were tested by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. The relative levels of Madcam1 protein expression in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h were calculated as the ratio between Madcam1 and GAPDH. The “DMSO” group was arbitrarily set to 100 %. G.-H. Exogenous Madcam1-Myc was measured in Bel-7402 transfected with GFP and Madcam1-Myc expressing plasmids and treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Representative WB images of are shown in panel G, the relative expression levels of exogenous Myc were calculated as the ratio to GFP, and the data are shown in panel H. The “DMSO” group was arbitrarily set to 100 %. I. Subcellular localization of Madcam1 in Bel-7402 and SMMC-7721 cells, as measured by the immunofluorescence assay. Scale bar, 5 µM. J. Madcam1 mRNA levels in Bel-7402 and SMMC-7721 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h, as measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The “DMSO” group was arbitrarily set to 100 %. K. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding DMSO or actinomycin D (final concentration 10 μg/ml) for further treatment for 24 h. Then, the RNA was extracted and measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The group treated with DMSO only was arbitrarily set to 100 %. L.-M. Doxo had no influence on Madcam1 protein stability. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 g/ml) for 2 h before being treated with CHX (final concentration 50 μg/ml) for the indicated times. Then, the cells were harvested for WB using anti-Madcam1 and anti-GAPDH antibodies L.. The Madcam1 protein levels were normalized to GAPDH, and the data are shown in panel M.. The group treated with CHX at the 0 h point was arbitrarily set to 100 %. N.-O. Time-dependent enrichment of eIF4E on the Madcam1 mRNA. Bel-7402 N. and SMMC- 7721 O. cells were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for the indicated times. Then, the RNA was extracted and subjected into RNA-IP assays using an anti-eIF4E antibody. The “0h” point was arbitrarily set to 100 %. **, Indicates statistical significance between “DMSO” and “Doxo” at specific time points. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.
Vascular Cell Adhesion Molecule 1 Vcam 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pmc10510463-47-16-25?v=Proteintech
Average 91 stars, based on 1 article reviews
vascular cell adhesion molecule 1 vcam 1 - by Bioz Stars, 2026-07
91/100 stars
  Buy from Supplier

91
Cusabio enzyme linked immunosorbent assay elisa kit
FIGURE 1 Nuciferine represses VCAM1 activation both in vitro and in vivo. (A) Chemical structure of nuciferine. (B) Cell viability test in EA.hy926 cells under 24 h treatment of nuciferine (0, 1, 2.5, 5, 10, 20, and 40 μmol/L). Relative mRNA level of VCAM1 verified by qPCR (C), protein level of VCAM1 verified by Western blot assay (D) (left panel), and the relative quantification data (D) (right panel), while EA.hy926 cells were pretreated with nuciferine (0, 1, 2.5, and 5 μmol/L) for 2 h, followed by 12 h incubation with TNFα (10 ng/mL) or vehicle. (E) Plasma VCAM1 level examined by the <t>ELISA</t> method from the indicated mice. (F) VCAM1 immunofluorescence staining of arterial endothelia tissues from the indicated mice; nuclei were visualized by DAPI staining (blue), and VCAM1 was visualized by an FITC-conjugated secondary antibody (green); the final data were captured under a fluorescence digital pathology scanner (magnification ×200; scale bar, 100 μm). All values are denoted as the means ± SD from five animal samples or at least three independent batches of cells. Each group contains the same amount of solvent. ud, undetectable. pp < 0.05 and ppp < 0.01 indicate statistically significant differences.
Enzyme Linked Immunosorbent Assay Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pm37841916-58-10-17?v=Cusabio
Average 91 stars, based on 1 article reviews
enzyme linked immunosorbent assay elisa kit - by Bioz Stars, 2026-07
91/100 stars
  Buy from Supplier

93
Cusabio human vascular cell adhesion molecule 1
FIGURE 1 Nuciferine represses VCAM1 activation both in vitro and in vivo. (A) Chemical structure of nuciferine. (B) Cell viability test in EA.hy926 cells under 24 h treatment of nuciferine (0, 1, 2.5, 5, 10, 20, and 40 μmol/L). Relative mRNA level of VCAM1 verified by qPCR (C), protein level of VCAM1 verified by Western blot assay (D) (left panel), and the relative quantification data (D) (right panel), while EA.hy926 cells were pretreated with nuciferine (0, 1, 2.5, and 5 μmol/L) for 2 h, followed by 12 h incubation with TNFα (10 ng/mL) or vehicle. (E) Plasma VCAM1 level examined by the <t>ELISA</t> method from the indicated mice. (F) VCAM1 immunofluorescence staining of arterial endothelia tissues from the indicated mice; nuclei were visualized by DAPI staining (blue), and VCAM1 was visualized by an FITC-conjugated secondary antibody (green); the final data were captured under a fluorescence digital pathology scanner (magnification ×200; scale bar, 100 μm). All values are denoted as the means ± SD from five animal samples or at least three independent batches of cells. Each group contains the same amount of solvent. ud, undetectable. pp < 0.05 and ppp < 0.01 indicate statistically significant differences.
Human Vascular Cell Adhesion Molecule 1, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pmc06416834-56-26-35?v=Cusabio
Average 93 stars, based on 1 article reviews
human vascular cell adhesion molecule 1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

93
Boster Bio vcam 1
FIGURE 1 Nuciferine represses VCAM1 activation both in vitro and in vivo. (A) Chemical structure of nuciferine. (B) Cell viability test in EA.hy926 cells under 24 h treatment of nuciferine (0, 1, 2.5, 5, 10, 20, and 40 μmol/L). Relative mRNA level of VCAM1 verified by qPCR (C), protein level of VCAM1 verified by Western blot assay (D) (left panel), and the relative quantification data (D) (right panel), while EA.hy926 cells were pretreated with nuciferine (0, 1, 2.5, and 5 μmol/L) for 2 h, followed by 12 h incubation with TNFα (10 ng/mL) or vehicle. (E) Plasma VCAM1 level examined by the <t>ELISA</t> method from the indicated mice. (F) VCAM1 immunofluorescence staining of arterial endothelia tissues from the indicated mice; nuclei were visualized by DAPI staining (blue), and VCAM1 was visualized by an FITC-conjugated secondary antibody (green); the final data were captured under a fluorescence digital pathology scanner (magnification ×200; scale bar, 100 μm). All values are denoted as the means ± SD from five animal samples or at least three independent batches of cells. Each group contains the same amount of solvent. ud, undetectable. pp < 0.05 and ppp < 0.01 indicate statistically significant differences.
Vcam 1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/pmc03933059-49-36-28?v=Boster+Bio
Average 93 stars, based on 1 article reviews
vcam 1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

90
SuperArray Bioscience Corporation vascular cell adhesion molecule-1
FIGURE 1 Nuciferine represses VCAM1 activation both in vitro and in vivo. (A) Chemical structure of nuciferine. (B) Cell viability test in EA.hy926 cells under 24 h treatment of nuciferine (0, 1, 2.5, 5, 10, 20, and 40 μmol/L). Relative mRNA level of VCAM1 verified by qPCR (C), protein level of VCAM1 verified by Western blot assay (D) (left panel), and the relative quantification data (D) (right panel), while EA.hy926 cells were pretreated with nuciferine (0, 1, 2.5, and 5 μmol/L) for 2 h, followed by 12 h incubation with TNFα (10 ng/mL) or vehicle. (E) Plasma VCAM1 level examined by the <t>ELISA</t> method from the indicated mice. (F) VCAM1 immunofluorescence staining of arterial endothelia tissues from the indicated mice; nuclei were visualized by DAPI staining (blue), and VCAM1 was visualized by an FITC-conjugated secondary antibody (green); the final data were captured under a fluorescence digital pathology scanner (magnification ×200; scale bar, 100 μm). All values are denoted as the means ± SD from five animal samples or at least three independent batches of cells. Each group contains the same amount of solvent. ud, undetectable. pp < 0.05 and ppp < 0.01 indicate statistically significant differences.
Vascular Cell Adhesion Molecule 1, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+cell+adhesion+molecule+1/10__1161_slash_circresaha__108__189746-48-77-81?v=SuperArray+Bioscience+Corporation
Average 90 stars, based on 1 article reviews
vascular cell adhesion molecule-1 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Figure 1: Doxorubicin induced apoptosis and reduced Madcam1 expression. A.-B. Doxo induced dose-dependent cleavage of Caspase substrates (CCS), as analyzed by WB using an anti-cleaved caspase substrate antibodies, in SMMC-7721 and Bel-7402 cells treated with DMSO or Doxo (final concentration 0.5-2.0 µg/ml) for 24 h. The representative western blots are shown in panel A. The CCS was calculated as the ratio between the levels of cleaved Caspase substrate and GAPDH, and the data are shown in panel B. The groups treated with 0.5 µg/ml Doxo were arbitrarily set to 100%. C. Doxo induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo luciferase kit from Promega, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. D. Doxo reduced cell proliferation, as measured by an MTT-based assay, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. E. Potential proteins that were regulated by Doxo. Endogenous expression of the indicated proteins were tested by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. The relative levels of Madcam1 protein expression in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h were calculated as the ratio between Madcam1 and GAPDH. The “DMSO” group was arbitrarily set to 100 %. G.-H. Exogenous Madcam1-Myc was measured in Bel-7402 transfected with GFP and Madcam1-Myc expressing plasmids and treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Representative WB images of are shown in panel G, the relative expression levels of exogenous Myc were calculated as the ratio to GFP, and the data are shown in panel H. The “DMSO” group was arbitrarily set to 100 %. I. Subcellular localization of Madcam1 in Bel-7402 and SMMC-7721 cells, as measured by the immunofluorescence assay. Scale bar, 5 µM. J. Madcam1 mRNA levels in Bel-7402 and SMMC-7721 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h, as measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The “DMSO” group was arbitrarily set to 100 %. K. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding DMSO or actinomycin D (final concentration 10 μg/ml) for further treatment for 24 h. Then, the RNA was extracted and measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The group treated with DMSO only was arbitrarily set to 100 %. L.-M. Doxo had no influence on Madcam1 protein stability. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 g/ml) for 2 h before being treated with CHX (final concentration 50 μg/ml) for the indicated times. Then, the cells were harvested for WB using anti-Madcam1 and anti-GAPDH antibodies L.. The Madcam1 protein levels were normalized to GAPDH, and the data are shown in panel M.. The group treated with CHX at the 0 h point was arbitrarily set to 100 %. N.-O. Time-dependent enrichment of eIF4E on the Madcam1 mRNA. Bel-7402 N. and SMMC- 7721 O. cells were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for the indicated times. Then, the RNA was extracted and subjected into RNA-IP assays using an anti-eIF4E antibody. The “0h” point was arbitrarily set to 100 %. **, Indicates statistical significance between “DMSO” and “Doxo” at specific time points. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.

Journal: Oncotarget

Article Title: Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.

doi: 10.18632/oncotarget.4373

Figure Lengend Snippet: Figure 1: Doxorubicin induced apoptosis and reduced Madcam1 expression. A.-B. Doxo induced dose-dependent cleavage of Caspase substrates (CCS), as analyzed by WB using an anti-cleaved caspase substrate antibodies, in SMMC-7721 and Bel-7402 cells treated with DMSO or Doxo (final concentration 0.5-2.0 µg/ml) for 24 h. The representative western blots are shown in panel A. The CCS was calculated as the ratio between the levels of cleaved Caspase substrate and GAPDH, and the data are shown in panel B. The groups treated with 0.5 µg/ml Doxo were arbitrarily set to 100%. C. Doxo induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo luciferase kit from Promega, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. D. Doxo reduced cell proliferation, as measured by an MTT-based assay, in cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. The “ DMSO” group was arbitrarily set to 100%. E. Potential proteins that were regulated by Doxo. Endogenous expression of the indicated proteins were tested by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. The relative levels of Madcam1 protein expression in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h were calculated as the ratio between Madcam1 and GAPDH. The “DMSO” group was arbitrarily set to 100 %. G.-H. Exogenous Madcam1-Myc was measured in Bel-7402 transfected with GFP and Madcam1-Myc expressing plasmids and treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Representative WB images of are shown in panel G, the relative expression levels of exogenous Myc were calculated as the ratio to GFP, and the data are shown in panel H. The “DMSO” group was arbitrarily set to 100 %. I. Subcellular localization of Madcam1 in Bel-7402 and SMMC-7721 cells, as measured by the immunofluorescence assay. Scale bar, 5 µM. J. Madcam1 mRNA levels in Bel-7402 and SMMC-7721 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h, as measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The “DMSO” group was arbitrarily set to 100 %. K. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding DMSO or actinomycin D (final concentration 10 μg/ml) for further treatment for 24 h. Then, the RNA was extracted and measured by qPCR assays. The Madcam1 levels were normalized to GAPDH. The group treated with DMSO only was arbitrarily set to 100 %. L.-M. Doxo had no influence on Madcam1 protein stability. Bel-7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 g/ml) for 2 h before being treated with CHX (final concentration 50 μg/ml) for the indicated times. Then, the cells were harvested for WB using anti-Madcam1 and anti-GAPDH antibodies L.. The Madcam1 protein levels were normalized to GAPDH, and the data are shown in panel M.. The group treated with CHX at the 0 h point was arbitrarily set to 100 %. N.-O. Time-dependent enrichment of eIF4E on the Madcam1 mRNA. Bel-7402 N. and SMMC- 7721 O. cells were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for the indicated times. Then, the RNA was extracted and subjected into RNA-IP assays using an anti-eIF4E antibody. The “0h” point was arbitrarily set to 100 %. **, Indicates statistical significance between “DMSO” and “Doxo” at specific time points. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.

Article Snippet: The cDNA fragments encoding human Madcam1 were purchased from Origene (Beijing, China) and subcloned into the pcDNA3.1 (+) vector with a C-terminal FLAG tag or into the pLJM-based lentiviral vector with a C-terminal Myc tag.

Techniques: Expressing, Concentration Assay, Western Blot, Activity Assay, Luciferase, MTT Assay, Transfection, Immunofluorescence

Figure 2: Madcam1 suppressed Doxorubicin-induced apoptosis in HCC cells. A.-B. CCS and Madcam1 in different cells that were treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h before harvest for WB using an anti-cleaved Caspase substrate antibody. Representative images of the WB are shown in panel A. The levels of CCS and Madcam1 were normalized to GAPDH, and the data are shown in panel B. The data from the “DMSO-treated” HL-7702 cells was arbitrarily set to 100 %. C.-D. Madcam1 overexpression reduced Doxo-induced apoptosis. Bel-7402 and SMMC-7721 cells infected with empty or Madcam1-Myc expressing lentiviral plasmids were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h before harvest for WB analysis using anti- cleaved Caspase substrate antibodies. Representative images of the WB are shown in panel C. The CCS levels were normalized to GAPDH, and the data are shown in panel D. The SMMC-7721 cells infected with the empty vector and treated with DMSO were arbitrarily set to 100 %. E.-F. Madcam1 knockdown reinforced Doxo-induced apoptosis. Control (infected with GFP-sh) and Madcam1 knockdown (infected with Madcam1-sh1 and –sh2, respectively) Bel-7402 or SMMC-7721 cells were treated with DMSO or Doxo (final concentration 2.0 µg/ ml) for 24 h before harvest for WB analysis using anti-cleaved Caspase substrate antibodies. Representative images of the WB are shown in panel E. The CCS levels were normalized to GAPDH, and the data are shown in panel F. The cells infected with Mad-sh1 and treated with DMSO were arbitrarily set to 100 %. G. Madcam1 prevented Doxo-induced apoptosis, as measured by a flow cytometer using an Annexin V-FITC early apoptosis detection kit, in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. H. Madcam1 reduced cleaved Caspase 3 expression, as measured by immunofluorescence assay, in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Scale bar, 20 µM. I. Madcam1 reduced Doxo-induced and Caspase 3/7 activity. Control (Mock) and Madcam1 overexpressing or knockdown Bel-7402 and SMMC-7721 cells were treated with DMSO or Doxo (final concentration 2.0 µg/ ml) for 24 h before harvest for testing the Caspase 3/7 activity using a Caspase 3/7 Glo luciferase kit. Data from the “Mock treated with DMSO” group were arbitrarily set to 100 %. J.-K. Time-dependent Caspase 3/7 activities after Doxo (final concentration 0.5 µg/ml) treatment in the indicated Bel-7402 J. and SMMC-7721 K. cells was measured by a Caspase 3/7 Glo luciferase kit from Promega. The data from the “Mock-0h” group were arbitrarily set to 100 %. **, p < 0.01 versus the Mock group at the same time point using the Student’s t test. L. Madcam1 knockdown reduced cell proliferation, as measured by an MTT-based assay, in Bel-7402 and SMMC-7721 cells. The initial cell number is 5,000, and the cells were cultured for another 5 days before the OD value was determined. M. Measurement of xenografts generated by Bel-7402 cells in vivo. The tumor size formed from the subcutaneous injection of Bel-7402 cells with the different indicated treatments was measured with calipers at 30 days after injection and calculated as 0.5 × L × W2 (n = 5 per group). The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.

Journal: Oncotarget

Article Title: Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.

doi: 10.18632/oncotarget.4373

Figure Lengend Snippet: Figure 2: Madcam1 suppressed Doxorubicin-induced apoptosis in HCC cells. A.-B. CCS and Madcam1 in different cells that were treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h before harvest for WB using an anti-cleaved Caspase substrate antibody. Representative images of the WB are shown in panel A. The levels of CCS and Madcam1 were normalized to GAPDH, and the data are shown in panel B. The data from the “DMSO-treated” HL-7702 cells was arbitrarily set to 100 %. C.-D. Madcam1 overexpression reduced Doxo-induced apoptosis. Bel-7402 and SMMC-7721 cells infected with empty or Madcam1-Myc expressing lentiviral plasmids were treated with same amount of DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h before harvest for WB analysis using anti- cleaved Caspase substrate antibodies. Representative images of the WB are shown in panel C. The CCS levels were normalized to GAPDH, and the data are shown in panel D. The SMMC-7721 cells infected with the empty vector and treated with DMSO were arbitrarily set to 100 %. E.-F. Madcam1 knockdown reinforced Doxo-induced apoptosis. Control (infected with GFP-sh) and Madcam1 knockdown (infected with Madcam1-sh1 and –sh2, respectively) Bel-7402 or SMMC-7721 cells were treated with DMSO or Doxo (final concentration 2.0 µg/ ml) for 24 h before harvest for WB analysis using anti-cleaved Caspase substrate antibodies. Representative images of the WB are shown in panel E. The CCS levels were normalized to GAPDH, and the data are shown in panel F. The cells infected with Mad-sh1 and treated with DMSO were arbitrarily set to 100 %. G. Madcam1 prevented Doxo-induced apoptosis, as measured by a flow cytometer using an Annexin V-FITC early apoptosis detection kit, in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. H. Madcam1 reduced cleaved Caspase 3 expression, as measured by immunofluorescence assay, in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. Scale bar, 20 µM. I. Madcam1 reduced Doxo-induced and Caspase 3/7 activity. Control (Mock) and Madcam1 overexpressing or knockdown Bel-7402 and SMMC-7721 cells were treated with DMSO or Doxo (final concentration 2.0 µg/ ml) for 24 h before harvest for testing the Caspase 3/7 activity using a Caspase 3/7 Glo luciferase kit. Data from the “Mock treated with DMSO” group were arbitrarily set to 100 %. J.-K. Time-dependent Caspase 3/7 activities after Doxo (final concentration 0.5 µg/ml) treatment in the indicated Bel-7402 J. and SMMC-7721 K. cells was measured by a Caspase 3/7 Glo luciferase kit from Promega. The data from the “Mock-0h” group were arbitrarily set to 100 %. **, p < 0.01 versus the Mock group at the same time point using the Student’s t test. L. Madcam1 knockdown reduced cell proliferation, as measured by an MTT-based assay, in Bel-7402 and SMMC-7721 cells. The initial cell number is 5,000, and the cells were cultured for another 5 days before the OD value was determined. M. Measurement of xenografts generated by Bel-7402 cells in vivo. The tumor size formed from the subcutaneous injection of Bel-7402 cells with the different indicated treatments was measured with calipers at 30 days after injection and calculated as 0.5 × L × W2 (n = 5 per group). The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.

Article Snippet: The cDNA fragments encoding human Madcam1 were purchased from Origene (Beijing, China) and subcloned into the pcDNA3.1 (+) vector with a C-terminal FLAG tag or into the pLJM-based lentiviral vector with a C-terminal Myc tag.

Techniques: Concentration Assay, Over Expression, Infection, Expressing, Plasmid Preparation, Knockdown, Control, Flow Cytometry, Immunofluorescence, Activity Assay, Luciferase, MTT Assay, Cell Culture, Generated, In Vivo, Injection

Figure 3: Madcam1 suppressed Doxorubicin in translation initiation A. Screening for possible Doxo target proteins, as analyzed by WB using a human apoptosis antibody array (containing 43 Targets) from Abcam. Bel-7402 cells were treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h before being subjected to the array analysis. The images of the array membrane are shown on the left. Shorter, shorter exposure; Longer, longer exposure. The spot positions of protein on the membrane are listed on the right. B. The same samples from panel A were subjected to WB for the confirmation of Doxo-induced apoptosis using anti-cleaved Caspase substrate antibodies. C. Screening targets before and after Madcam1 knockdown. Bel-7402 cells infected with GFP-sh or Madcam1-sh1 were harvested for WB using the array described in panel A. Shorter, shorter exposure; Longer, longer exposure. D. Madcam1-sh1knockdown efficiency in the samples from panel C. E. Representative western blots for the indicated proteins in Bel-7402 and HL-7702 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. Representative western blots of the indicated proteins in Bel-7402 cells infected with GFP-sh, Madcam1-sh1 or Madcam1–sh2. G.-H. mRNA levels in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h G. or in Bel-7402 cells infected with GFP-sh or Madcam1-sh1 H.. The mRNA levels were measured by qPCR assays. The levels in the “DMSO” or “GFP-sh” groups were arbitrarily set to 100 %. I. Doxo had no impact on protein stability. Bel- 7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding CHX for the indicated times. Then, the cell lysates were prepared for WB. J. Madcam1 had no effect on protein stability. Bel-7402 cells stably transfected with the empty or Madcam1-Myc expressing plasmids were treated with CHX for the indicated times. Then, the cell lysates were prepared for WB. K. Doxo and Madcam1 had opposite influences on eIF4E binding. The RNA was extracted from Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h (upper panel) or Bel-7402 cells infected with GFP-sh or Madcam1-sh1 (lower panel), and subjected to RNA-IP assays using anti-eIF4E antibodies. The data from the “DMSO” or “GFP-sh” groups were arbitrarily set to 100 %. L.-M. Inhibiting protein synthesis induced apoptosis. Bel-7402, HL-7702 and SMMC-7721 cells were treated with DMSO or CHX (final concentration 50 μg/ml) for 24 h before harvest for WB using anti-cleaved Caspase substrate antibodies. Representative images of the WB are shown in panel L. The relative CCS levels were calculated as the ratio to GAPDH, and the data are shown in the panel M. The data are shown as the means + SD from three independent experiments. **, p < 0.01 using the Student’s t test.

Journal: Oncotarget

Article Title: Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.

doi: 10.18632/oncotarget.4373

Figure Lengend Snippet: Figure 3: Madcam1 suppressed Doxorubicin in translation initiation A. Screening for possible Doxo target proteins, as analyzed by WB using a human apoptosis antibody array (containing 43 Targets) from Abcam. Bel-7402 cells were treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h before being subjected to the array analysis. The images of the array membrane are shown on the left. Shorter, shorter exposure; Longer, longer exposure. The spot positions of protein on the membrane are listed on the right. B. The same samples from panel A were subjected to WB for the confirmation of Doxo-induced apoptosis using anti-cleaved Caspase substrate antibodies. C. Screening targets before and after Madcam1 knockdown. Bel-7402 cells infected with GFP-sh or Madcam1-sh1 were harvested for WB using the array described in panel A. Shorter, shorter exposure; Longer, longer exposure. D. Madcam1-sh1knockdown efficiency in the samples from panel C. E. Representative western blots for the indicated proteins in Bel-7402 and HL-7702 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h. F. Representative western blots of the indicated proteins in Bel-7402 cells infected with GFP-sh, Madcam1-sh1 or Madcam1–sh2. G.-H. mRNA levels in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h G. or in Bel-7402 cells infected with GFP-sh or Madcam1-sh1 H.. The mRNA levels were measured by qPCR assays. The levels in the “DMSO” or “GFP-sh” groups were arbitrarily set to 100 %. I. Doxo had no impact on protein stability. Bel- 7402 cells were pretreated with DMSO or Doxo (final concentration 2.0 µg/ml) for 2 h before adding CHX for the indicated times. Then, the cell lysates were prepared for WB. J. Madcam1 had no effect on protein stability. Bel-7402 cells stably transfected with the empty or Madcam1-Myc expressing plasmids were treated with CHX for the indicated times. Then, the cell lysates were prepared for WB. K. Doxo and Madcam1 had opposite influences on eIF4E binding. The RNA was extracted from Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h (upper panel) or Bel-7402 cells infected with GFP-sh or Madcam1-sh1 (lower panel), and subjected to RNA-IP assays using anti-eIF4E antibodies. The data from the “DMSO” or “GFP-sh” groups were arbitrarily set to 100 %. L.-M. Inhibiting protein synthesis induced apoptosis. Bel-7402, HL-7702 and SMMC-7721 cells were treated with DMSO or CHX (final concentration 50 μg/ml) for 24 h before harvest for WB using anti-cleaved Caspase substrate antibodies. Representative images of the WB are shown in panel L. The relative CCS levels were calculated as the ratio to GAPDH, and the data are shown in the panel M. The data are shown as the means + SD from three independent experiments. **, p < 0.01 using the Student’s t test.

Article Snippet: The cDNA fragments encoding human Madcam1 were purchased from Origene (Beijing, China) and subcloned into the pcDNA3.1 (+) vector with a C-terminal FLAG tag or into the pLJM-based lentiviral vector with a C-terminal Myc tag.

Techniques: Ab Array, Concentration Assay, Membrane, Knockdown, Infection, Western Blot, Stable Transfection, Transfection, Expressing, Binding Assay

Figure 4: Doxorubicin and Madcam1 had opposite effects on eIF4E. A. Doxo reduced 4EBP1 phosphorylation. Phosphorylation of translation-associated proteins was detected in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h before harvest for WB using the indicated antibodies. B. p-4EBP1 and 4EBP1 were detected by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h before harvest. C. Madcam1 overexpression induced 4EBP1 phosphorylation, as detected by WB, in Bel-7402 cells transfected with empty or Madcam1-Myc expressing plasmids. D. Madcam1 knockdown reduced 4EBP1 phosphorylation, as detected by WB, in Bel-7402 cells infected with GFP-sh, Madcam1-sh1 or Madcam1–sh2. E. Doxo induced 4EBP1 binding to eIF4E. Bel-7402 cells were treated with DMSO or increasing concentrations of Doxo (final concentration from 0.5-2.5 µg/ml) for 5 h before harvest in IP lysis buffer. Endogenous eIF4E was then immunoprecipitated with an anti-eIF4E antibody and 4EBP1 co-immunoprecipitation was detected by WB. F. Madcam1 reduced 4EBP1 binding to eIF4E. Endogenous eIF4E was immunoprecipitated with an anti-eIF4E antibody and 4EBP1 co-immunoprecipitation was detected by WB for control (transfected with Empty vector) and Madcam1-Myc transfected Bel-7402 cells, using increasing amounts of ectopically expressed Madcam1-Myc. G. Identification of the subcellular localization of Madcam1. Co-localization of Madcam1 and possible organelles was analyzed in Bel-7402 cells by immunofluorescence assays using a combination of anti-Madcam1 (red) and anti-LC3B (autophagosome marker, green), anti-COX IV (mitochondria marker, green), anti- Calnexin (endoplasmic reticulum (ER) marker, green) or anti-NUP98 (nuclear envelop marker, green) antibodies. The area indicated by the square was enlarged on the right side. Scale bar, 10 µM. H. Madcam1 reversed Doxo-induced dephosphorylation of 4EBP1. Bel-7402 cells were treated with or without Doxo (final concentration 2.0 µg/ml) for 4 h in the presence or absence of ectopically expressed Madcam1- Myc before harvest for WB using anti-p-4EBP1 and 4EBP1 antibodies. I. Madcam1 prevented Doxo-induced protein down-regulation. Bel-7402 cells were treated as described in Figure 4H and were harvested for WB using the indicated antibodies. J. Madcam1 inhibited Doxo-induced dissociation of eIF4E from the mRNA. The RNA was extracted from Bel-7402 cells that were treated as in Figure 4h for RNA-IP assays using anti-eIF4E antibodies. The data from the “Mock” group were arbitrarily set to 100 %. The data are shown as the means + SD from three independent experiments (including WB). *, p < 0.05 using the Student’s t test.

Journal: Oncotarget

Article Title: Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.

doi: 10.18632/oncotarget.4373

Figure Lengend Snippet: Figure 4: Doxorubicin and Madcam1 had opposite effects on eIF4E. A. Doxo reduced 4EBP1 phosphorylation. Phosphorylation of translation-associated proteins was detected in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h before harvest for WB using the indicated antibodies. B. p-4EBP1 and 4EBP1 were detected by WB in Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h before harvest. C. Madcam1 overexpression induced 4EBP1 phosphorylation, as detected by WB, in Bel-7402 cells transfected with empty or Madcam1-Myc expressing plasmids. D. Madcam1 knockdown reduced 4EBP1 phosphorylation, as detected by WB, in Bel-7402 cells infected with GFP-sh, Madcam1-sh1 or Madcam1–sh2. E. Doxo induced 4EBP1 binding to eIF4E. Bel-7402 cells were treated with DMSO or increasing concentrations of Doxo (final concentration from 0.5-2.5 µg/ml) for 5 h before harvest in IP lysis buffer. Endogenous eIF4E was then immunoprecipitated with an anti-eIF4E antibody and 4EBP1 co-immunoprecipitation was detected by WB. F. Madcam1 reduced 4EBP1 binding to eIF4E. Endogenous eIF4E was immunoprecipitated with an anti-eIF4E antibody and 4EBP1 co-immunoprecipitation was detected by WB for control (transfected with Empty vector) and Madcam1-Myc transfected Bel-7402 cells, using increasing amounts of ectopically expressed Madcam1-Myc. G. Identification of the subcellular localization of Madcam1. Co-localization of Madcam1 and possible organelles was analyzed in Bel-7402 cells by immunofluorescence assays using a combination of anti-Madcam1 (red) and anti-LC3B (autophagosome marker, green), anti-COX IV (mitochondria marker, green), anti- Calnexin (endoplasmic reticulum (ER) marker, green) or anti-NUP98 (nuclear envelop marker, green) antibodies. The area indicated by the square was enlarged on the right side. Scale bar, 10 µM. H. Madcam1 reversed Doxo-induced dephosphorylation of 4EBP1. Bel-7402 cells were treated with or without Doxo (final concentration 2.0 µg/ml) for 4 h in the presence or absence of ectopically expressed Madcam1- Myc before harvest for WB using anti-p-4EBP1 and 4EBP1 antibodies. I. Madcam1 prevented Doxo-induced protein down-regulation. Bel-7402 cells were treated as described in Figure 4H and were harvested for WB using the indicated antibodies. J. Madcam1 inhibited Doxo-induced dissociation of eIF4E from the mRNA. The RNA was extracted from Bel-7402 cells that were treated as in Figure 4h for RNA-IP assays using anti-eIF4E antibodies. The data from the “Mock” group were arbitrarily set to 100 %. The data are shown as the means + SD from three independent experiments (including WB). *, p < 0.05 using the Student’s t test.

Article Snippet: The cDNA fragments encoding human Madcam1 were purchased from Origene (Beijing, China) and subcloned into the pcDNA3.1 (+) vector with a C-terminal FLAG tag or into the pLJM-based lentiviral vector with a C-terminal Myc tag.

Techniques: Phospho-proteomics, Concentration Assay, Over Expression, Transfection, Expressing, Knockdown, Infection, Binding Assay, Lysis, Immunoprecipitation, Control, Plasmid Preparation, Immunofluorescence, Marker, De-Phosphorylation Assay

Figure 5: Doxorubicin inhibited while Madcam1 stimulated AKT. A. Screening for possible signaling nodes that were regulated by both Doxo and Madcam1. Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h as well as Bel-7402 cells infected with GFP-sh or Madcam1-sh1 were harvested and subjected to the Pathscan™ antibody array (CST). The array images are shown on the left side, and the spots representing the positive control and p-AKT (Thr308) are indicated on the right side by the square and rectangle, respectively. B.-C. Verification of Doxo-induced AKT de-phosphorylation. Western blots of p-AKT and AKT from Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h B.. The levels of p-AKT in Bel-7402 and SMMC-7721 cells were normalized to AKT C.. The data from the “DMSO” group were arbitrarily set to 100%. D.-E. Madcam1 overexpression induced AKT phosphorylation. Representative western blots of p-AKT and AKT from Bel-7402 cells transfected with the empty or Madcam1- Myc expressing plasmids D.. The p-AKT levels from Bel-7402 and SMMC-7721 cells were normalized to f AKT, and the data from the “Empty” group were arbitrarily set to 100% E..F.-G. Madcam1 knockdown reduced AKT phosphorylation. Representative western blots of p-AKT and AKT from Bel-7402 cells infected with GFP-sh, Madcam1-sh1 or Madcam1–sh2 F.. The p-AKT levels from Bel-7402 and SMMC-7721 cells were normalized to AKT, and the data from the “GFP-sh” group were arbitrarily set to 100% G..H.-I. Representative images of TMA stained with anti-Madcam1 or anti-p-AKT antibodies. Scale bar, 200 M H.. The TMA data were analyzed using the χ2 test I.. J.-K. Blockage of PI3K/AKT inhibited 4EBP1 phosphorylation. Representative western blots of the indicated proteins from Bel-7402 cells treated with DMSO or Wortmannin (final concentration 50 μM) for 4 h J.. The ratio between p-4EBP1 and 4EBP1 are shown in panel K.. The data from the “DMSO” group were arbitrarily set to 100%. L. Blockage of PI3K/AKT inhibited eIF4E binding to the mRNA, as measured by RNA-IP followed by qPCR using anti-eIF4E antibodies and the indicated primer sets, in Bel-7402 cells treated with DMSO or Wortmannin (final concentration 50 μM) for 4 h. The data from the “DMSO” group were arbitrarily set to 100%. M.-N. Blockage of PI3K/AKT reduced protein expression. Western blots of the indicated proteins from Bel-7402 cells treated with same amount of DMSO or Wortmannin (final concentration 50 μM) for 24 h. Representative images of the WB are shown in panel M. The relative levels of the indicated proteins were calculated as the ratio to GAPDH, and the data are shown in panel N. The data from the “DMSO” group were arbitrarily set to 100%. O. Blockage of PI3K/AKT induced apoptosis, as measured by a Caspase 3/7 Glo-luciferase kit, in Bel-7402 and SMMC-7721 cells treated with DMSO or Wortmannin (final concentration 50 μM) for 24 h. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.

Journal: Oncotarget

Article Title: Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.

doi: 10.18632/oncotarget.4373

Figure Lengend Snippet: Figure 5: Doxorubicin inhibited while Madcam1 stimulated AKT. A. Screening for possible signaling nodes that were regulated by both Doxo and Madcam1. Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h as well as Bel-7402 cells infected with GFP-sh or Madcam1-sh1 were harvested and subjected to the Pathscan™ antibody array (CST). The array images are shown on the left side, and the spots representing the positive control and p-AKT (Thr308) are indicated on the right side by the square and rectangle, respectively. B.-C. Verification of Doxo-induced AKT de-phosphorylation. Western blots of p-AKT and AKT from Bel-7402 cells treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 4 h B.. The levels of p-AKT in Bel-7402 and SMMC-7721 cells were normalized to AKT C.. The data from the “DMSO” group were arbitrarily set to 100%. D.-E. Madcam1 overexpression induced AKT phosphorylation. Representative western blots of p-AKT and AKT from Bel-7402 cells transfected with the empty or Madcam1- Myc expressing plasmids D.. The p-AKT levels from Bel-7402 and SMMC-7721 cells were normalized to f AKT, and the data from the “Empty” group were arbitrarily set to 100% E..F.-G. Madcam1 knockdown reduced AKT phosphorylation. Representative western blots of p-AKT and AKT from Bel-7402 cells infected with GFP-sh, Madcam1-sh1 or Madcam1–sh2 F.. The p-AKT levels from Bel-7402 and SMMC-7721 cells were normalized to AKT, and the data from the “GFP-sh” group were arbitrarily set to 100% G..H.-I. Representative images of TMA stained with anti-Madcam1 or anti-p-AKT antibodies. Scale bar, 200 M H.. The TMA data were analyzed using the χ2 test I.. J.-K. Blockage of PI3K/AKT inhibited 4EBP1 phosphorylation. Representative western blots of the indicated proteins from Bel-7402 cells treated with DMSO or Wortmannin (final concentration 50 μM) for 4 h J.. The ratio between p-4EBP1 and 4EBP1 are shown in panel K.. The data from the “DMSO” group were arbitrarily set to 100%. L. Blockage of PI3K/AKT inhibited eIF4E binding to the mRNA, as measured by RNA-IP followed by qPCR using anti-eIF4E antibodies and the indicated primer sets, in Bel-7402 cells treated with DMSO or Wortmannin (final concentration 50 μM) for 4 h. The data from the “DMSO” group were arbitrarily set to 100%. M.-N. Blockage of PI3K/AKT reduced protein expression. Western blots of the indicated proteins from Bel-7402 cells treated with same amount of DMSO or Wortmannin (final concentration 50 μM) for 24 h. Representative images of the WB are shown in panel M. The relative levels of the indicated proteins were calculated as the ratio to GAPDH, and the data are shown in panel N. The data from the “DMSO” group were arbitrarily set to 100%. O. Blockage of PI3K/AKT induced apoptosis, as measured by a Caspase 3/7 Glo-luciferase kit, in Bel-7402 and SMMC-7721 cells treated with DMSO or Wortmannin (final concentration 50 μM) for 24 h. The data are shown as the means + SD from three independent experiments (including WB). **, p < 0.01 using the Student’s t test.

Article Snippet: The cDNA fragments encoding human Madcam1 were purchased from Origene (Beijing, China) and subcloned into the pcDNA3.1 (+) vector with a C-terminal FLAG tag or into the pLJM-based lentiviral vector with a C-terminal Myc tag.

Techniques: Concentration Assay, Infection, Ab Array, Positive Control, De-Phosphorylation Assay, Western Blot, Over Expression, Phospho-proteomics, Transfection, Expressing, Knockdown, Staining, Binding Assay, Luciferase

Figure 6: The interaction between Madcam1 and AKT was critical for the regulation of apoptosis. A. Madcam1 bound AKT. Madcam1-FLAG was co-transfected with AKT-Myc into Bel-7402 cells, as indicated. Madcam1 and AKT associations were examined by reciprocal co-IP, as indicated. B. The interaction between endogenous AKT and Madcam1 was measured by reciprocal co-IP using the indicated antibodies. A control immunoglobulin G (IgG) was used as the negative control for IP. C. Red Fluorescent emissions in Bel-7402 and SMMC-7721 cells co-transfected with exogenous AKT-Myc and Madcam1-FLAG were detected by a Duolink™ proximity ligation (PLA) kit. The areas with red signals were indicated and enlarged by a square. Scale bar, 20 μM. The arrow indicates cells co- transfected with AKT-Myc and Madcam1-FLAG, while the asterisk indicates cells without successful transfection or with transfection of either AKT-Myc or Madcam1-FLAG. D. The interactions between endogenous AKT and Madcam1 in Bel-7402 and SMMC-7721 cells were detected by a Duolink™ proximity ligation (PLA) kit using anti-AKT and anti-Madcam1 antibodies, as indicated. Parallel negative controls were also performed using no antibody (Ab) or only one antibody as indicated. The areas with red signals were indicated and enlarged by a square. Scale bar, 100 μM. The asterisk indicates strong interaction signals. Ms, mouse origin; Rb, rabbit origin. E.-F. AKT acted as a downstream effecter of Madcam1. Apoptosis was evaluated by a Caspase 3/7 Glo-luciferase kit E. in Bel-7402 and SMMC-7721 cells with or without AKT or Madcam1 knockdown in the presence or absence of ectopically expressed Madcam1-FLAG or AKT-Myc. Cell proliferation was measured by an MTT-based assay F.. The data from cells without any treatment were arbitrarily set to 100 %. The data are shown as the means + SD from three independent experiments. **, p < 0.01 using the Student’s t test.

Journal: Oncotarget

Article Title: Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.

doi: 10.18632/oncotarget.4373

Figure Lengend Snippet: Figure 6: The interaction between Madcam1 and AKT was critical for the regulation of apoptosis. A. Madcam1 bound AKT. Madcam1-FLAG was co-transfected with AKT-Myc into Bel-7402 cells, as indicated. Madcam1 and AKT associations were examined by reciprocal co-IP, as indicated. B. The interaction between endogenous AKT and Madcam1 was measured by reciprocal co-IP using the indicated antibodies. A control immunoglobulin G (IgG) was used as the negative control for IP. C. Red Fluorescent emissions in Bel-7402 and SMMC-7721 cells co-transfected with exogenous AKT-Myc and Madcam1-FLAG were detected by a Duolink™ proximity ligation (PLA) kit. The areas with red signals were indicated and enlarged by a square. Scale bar, 20 μM. The arrow indicates cells co- transfected with AKT-Myc and Madcam1-FLAG, while the asterisk indicates cells without successful transfection or with transfection of either AKT-Myc or Madcam1-FLAG. D. The interactions between endogenous AKT and Madcam1 in Bel-7402 and SMMC-7721 cells were detected by a Duolink™ proximity ligation (PLA) kit using anti-AKT and anti-Madcam1 antibodies, as indicated. Parallel negative controls were also performed using no antibody (Ab) or only one antibody as indicated. The areas with red signals were indicated and enlarged by a square. Scale bar, 100 μM. The asterisk indicates strong interaction signals. Ms, mouse origin; Rb, rabbit origin. E.-F. AKT acted as a downstream effecter of Madcam1. Apoptosis was evaluated by a Caspase 3/7 Glo-luciferase kit E. in Bel-7402 and SMMC-7721 cells with or without AKT or Madcam1 knockdown in the presence or absence of ectopically expressed Madcam1-FLAG or AKT-Myc. Cell proliferation was measured by an MTT-based assay F.. The data from cells without any treatment were arbitrarily set to 100 %. The data are shown as the means + SD from three independent experiments. **, p < 0.01 using the Student’s t test.

Article Snippet: The cDNA fragments encoding human Madcam1 were purchased from Origene (Beijing, China) and subcloned into the pcDNA3.1 (+) vector with a C-terminal FLAG tag or into the pLJM-based lentiviral vector with a C-terminal Myc tag.

Techniques: Transfection, Co-Immunoprecipitation Assay, Control, Negative Control, Ligation, Luciferase, Knockdown, MTT Assay

Figure 7: Doxorubicin sensitivity depended on the p-AKT level. A. Western blots of p-AKT, AKT and Madcam1 in HCC tissues and adjacent normal liver tissues. Normal samples #1, 2, and 3 were paired with the HCC samples #1, 2, and 3, while HCC samples #4, 5, 6, and 7 had no paired normal samples. B.-C. Sequential overexpression of AKT and Madcam1 increased AKT phosphorylation, as measured by WB, in HL-7702 cells transfected with AKT-Myc and increasing concentrations (0.5- 1.5 µg) of Madcam1-Myc expressing plasmids. Endogenous protein expression in Bel-7402 cells was also examined B.. The data were shown as the p-AKT to AKT ratio in panel C., and the data from the “Mock (without treatment)” group were arbitrarily set to 100 %. D.-E. Sequential overexpression of AKT and Madcam1 increased protein expression. Western blots of the indicated proteins from HL-7702 cells with the same treatment as in Figures 7B and 7C. Protein expression in the Bel-7402 cells served as the control. Representative images of the WB are shown in panel D. The relative levels of the indicated proteins were calculated as the ratio to GAPDH, and the data are shown in panel E. The data from the “HL-7702 Mock (without treatment)” group were arbitrarily set to 100%. F. Sequential overexpression of AKT and Madcam1 recruited eIF4E binding to the mRNAs, as measured by RNA-IP followed by RT-qPCR using anti-eiF4E antibodies and the indicated primer sets, in HL-7702 cells with the same treatment as in Figure 7B-7C. Bel-7402 cells served as the control. The data from the “HL-7702 Mock (without treatment)” group were arbitrarily set to 100 %. G. Sequential overexpression of AKT and Madcam1 increased Doxo sensitivity. HL-7702 cells with the same treatment as in Figure 7B-7C were treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h before harvest for Caspase 3/7 activity measurements using a Caspase Glo-luciferase kit. Bel-7402 cells served as the control. The data from the “HL-7702 Mock-DMSO” group were arbitrarily set to 100 %. H.-I. Sequential knockdown of Madcam1 and AKT reduced AKT phosphorylation. Bel-7402 cells infected with Madcam-sh1 and AKT-sh1 and treated with or without Wortmannin (final concentration 50 μM) for 24 h were subjected to WB to detect p-AKT, AKT and Madcam1 H.. The data were shown as the p-AKT to AKT ratio in panel I., and the data from the untreated cells were arbitrarily set to 100 %. J. Sequential knockdown of Madcam1 and AKT reduced Doxo-induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo-luciferase kit, in Bel-7402 cells with the same treatment as in Figure 7G-7H. The data from the control DMSO-treated cells were arbitrarily set to 100 %. K. Illustration of a possible mechanism underlying the critical interaction between Madcam1 and AKT in the Doxorubicin-mediated regulation of apoptosis in HCC cells. The data are shown as the means + SD from three independent experiments (including WB, except panel A). *, p < 0.05 and **, p < 0.01 using the Student’s t test.

Journal: Oncotarget

Article Title: Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.

doi: 10.18632/oncotarget.4373

Figure Lengend Snippet: Figure 7: Doxorubicin sensitivity depended on the p-AKT level. A. Western blots of p-AKT, AKT and Madcam1 in HCC tissues and adjacent normal liver tissues. Normal samples #1, 2, and 3 were paired with the HCC samples #1, 2, and 3, while HCC samples #4, 5, 6, and 7 had no paired normal samples. B.-C. Sequential overexpression of AKT and Madcam1 increased AKT phosphorylation, as measured by WB, in HL-7702 cells transfected with AKT-Myc and increasing concentrations (0.5- 1.5 µg) of Madcam1-Myc expressing plasmids. Endogenous protein expression in Bel-7402 cells was also examined B.. The data were shown as the p-AKT to AKT ratio in panel C., and the data from the “Mock (without treatment)” group were arbitrarily set to 100 %. D.-E. Sequential overexpression of AKT and Madcam1 increased protein expression. Western blots of the indicated proteins from HL-7702 cells with the same treatment as in Figures 7B and 7C. Protein expression in the Bel-7402 cells served as the control. Representative images of the WB are shown in panel D. The relative levels of the indicated proteins were calculated as the ratio to GAPDH, and the data are shown in panel E. The data from the “HL-7702 Mock (without treatment)” group were arbitrarily set to 100%. F. Sequential overexpression of AKT and Madcam1 recruited eIF4E binding to the mRNAs, as measured by RNA-IP followed by RT-qPCR using anti-eiF4E antibodies and the indicated primer sets, in HL-7702 cells with the same treatment as in Figure 7B-7C. Bel-7402 cells served as the control. The data from the “HL-7702 Mock (without treatment)” group were arbitrarily set to 100 %. G. Sequential overexpression of AKT and Madcam1 increased Doxo sensitivity. HL-7702 cells with the same treatment as in Figure 7B-7C were treated with DMSO or Doxo (final concentration 2.0 µg/ml) for 24 h before harvest for Caspase 3/7 activity measurements using a Caspase Glo-luciferase kit. Bel-7402 cells served as the control. The data from the “HL-7702 Mock-DMSO” group were arbitrarily set to 100 %. H.-I. Sequential knockdown of Madcam1 and AKT reduced AKT phosphorylation. Bel-7402 cells infected with Madcam-sh1 and AKT-sh1 and treated with or without Wortmannin (final concentration 50 μM) for 24 h were subjected to WB to detect p-AKT, AKT and Madcam1 H.. The data were shown as the p-AKT to AKT ratio in panel I., and the data from the untreated cells were arbitrarily set to 100 %. J. Sequential knockdown of Madcam1 and AKT reduced Doxo-induced Caspase 3/7 activity, as measured by a Caspase 3/7 Glo-luciferase kit, in Bel-7402 cells with the same treatment as in Figure 7G-7H. The data from the control DMSO-treated cells were arbitrarily set to 100 %. K. Illustration of a possible mechanism underlying the critical interaction between Madcam1 and AKT in the Doxorubicin-mediated regulation of apoptosis in HCC cells. The data are shown as the means + SD from three independent experiments (including WB, except panel A). *, p < 0.05 and **, p < 0.01 using the Student’s t test.

Article Snippet: The cDNA fragments encoding human Madcam1 were purchased from Origene (Beijing, China) and subcloned into the pcDNA3.1 (+) vector with a C-terminal FLAG tag or into the pLJM-based lentiviral vector with a C-terminal Myc tag.

Techniques: Western Blot, Over Expression, Phospho-proteomics, Transfection, Expressing, Control, Binding Assay, Quantitative RT-PCR, Concentration Assay, Activity Assay, Luciferase, Knockdown, Infection

FIGURE 1 Nuciferine represses VCAM1 activation both in vitro and in vivo. (A) Chemical structure of nuciferine. (B) Cell viability test in EA.hy926 cells under 24 h treatment of nuciferine (0, 1, 2.5, 5, 10, 20, and 40 μmol/L). Relative mRNA level of VCAM1 verified by qPCR (C), protein level of VCAM1 verified by Western blot assay (D) (left panel), and the relative quantification data (D) (right panel), while EA.hy926 cells were pretreated with nuciferine (0, 1, 2.5, and 5 μmol/L) for 2 h, followed by 12 h incubation with TNFα (10 ng/mL) or vehicle. (E) Plasma VCAM1 level examined by the ELISA method from the indicated mice. (F) VCAM1 immunofluorescence staining of arterial endothelia tissues from the indicated mice; nuclei were visualized by DAPI staining (blue), and VCAM1 was visualized by an FITC-conjugated secondary antibody (green); the final data were captured under a fluorescence digital pathology scanner (magnification ×200; scale bar, 100 μm). All values are denoted as the means ± SD from five animal samples or at least three independent batches of cells. Each group contains the same amount of solvent. ud, undetectable. pp < 0.05 and ppp < 0.01 indicate statistically significant differences.

Journal: Frontiers in pharmacology

Article Title: Nuciferine induces autophagy to relieve vascular cell adhesion molecule 1 activation via repressing the Akt/mTOR/AP1 signal pathway in the vascular endothelium.

doi: 10.3389/fphar.2023.1264324

Figure Lengend Snippet: FIGURE 1 Nuciferine represses VCAM1 activation both in vitro and in vivo. (A) Chemical structure of nuciferine. (B) Cell viability test in EA.hy926 cells under 24 h treatment of nuciferine (0, 1, 2.5, 5, 10, 20, and 40 μmol/L). Relative mRNA level of VCAM1 verified by qPCR (C), protein level of VCAM1 verified by Western blot assay (D) (left panel), and the relative quantification data (D) (right panel), while EA.hy926 cells were pretreated with nuciferine (0, 1, 2.5, and 5 μmol/L) for 2 h, followed by 12 h incubation with TNFα (10 ng/mL) or vehicle. (E) Plasma VCAM1 level examined by the ELISA method from the indicated mice. (F) VCAM1 immunofluorescence staining of arterial endothelia tissues from the indicated mice; nuclei were visualized by DAPI staining (blue), and VCAM1 was visualized by an FITC-conjugated secondary antibody (green); the final data were captured under a fluorescence digital pathology scanner (magnification ×200; scale bar, 100 μm). All values are denoted as the means ± SD from five animal samples or at least three independent batches of cells. Each group contains the same amount of solvent. ud, undetectable. pp < 0.05 and ppp < 0.01 indicate statistically significant differences.

Article Snippet: VCAM1 content in mice plasma was determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit obtained from Cusabio (CSB-E04754m, Wuhan, China).

Techniques: Activation Assay, In Vitro, In Vivo, Western Blot, Incubation, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Staining, Solvent